Axios Vitals: CDC defends mask guidance amid confusion

Plus: Johns Hopkins digs in on data discrepancies | Monday, May 17, 2021

Open in app View in browser   Presented By Blue Cross Blue Shield Association   Vitals By Tina Reed ·May 17, 2021 Good morning. This is my very first edition taking over the reins at Vitals. I am so excited to be writing for such an engaged group of readers. I intend to honor the time you take here every morning. A little about myself: I've been reporting on health care news for more than a decade. I really like telling interesting stories about how the business of health care works — from hospitals to health tech to VC funding — and how that ultimately winds up impacting the reason we're all here: the patient. I look forward to starting a conversation with you and hearing your tips and feedback. You can reach me at tina.reed@axios.com or find me on Twitter at @TreedinDC. Today's word count: 831, or a 3-minute read. (Apologies for the late send this morning. We had some technical difficulties.)     1 big thing: Masking guidance spurs confusion Illustration: Sarah Grillo/Axios   The CDC's surprise guidance last week freeing the fully vaccinated to go maskless indoors sowed plenty of confusion across the country— even earning the "Saturday Night Live" treatment for all the questions it spurred. Why it matters: With plenty of Americans still unvaccinated — and without any good way to confirm who has been vaccinated — some experts worry this could put many at increased risk. Driving the news: CDC director Rochelle Walensky made the rounds on the Sunday news shows defending the guidance. Walensky said the CDC is following the science, pointing specifically to new evidence the vaccinated rarely transmit the virus. "This is not permission for widespread removal of masks," Walensky told ABC News' Martha Raddatz. "These decisions have to be made at the jurisdictional level." But among those joining the chorus of criticism were public health experts like Leana Wen, visiting professor at the George Washington University Milken Institute School of Public Health. She was among those who previously called out the department for being too cautious. The course reversal "could end up increasing confusion, removing incentives for those yet to be inoculated and delaying the eventual goal of herd immunity that would get society truly back to normal," Wen wrote in the Washington Post. Among key concerns: Plenty of Americans haven't had a chance to get fully vaccinated yet, or can't get shots, including children younger than 12. The CDC clarified Saturday that schools should continue to follow guidance recommending masks indoors for the rest of this school year. What's next: Several major companies, including Walmart, Costco, Trader Joe's and Publix announced they would no longer require masks for vaccinated customers. Home Depot and Target are among those who've told customers to keep masks on for now.     2. Hesitant Americans cite inaccurate side effects Data: Harris Poll; Chart: Danielle Alberti/Axios An alarming amount of vaccine-hesitant people who list side effects as a top concern falsely believe the vaccines cause death, DNA alteration, infertility or birth defects according to recent Harris polling. Respondents also listed blood clots, which are a real side effect of some coronavirus vaccines, but extremely rare. Why it matters: This survey suggests that misinformation or a skewed understanding of risk may be behind a sizable portion of vaccine hesitancy, Axios' Caitlin Owens reports. Share this story.     3. Scoop: Johns Hopkins digs in on data discrepancies Illustration: Sarah Grillo/Axios   Johns Hopkins University is launching a "pandemic data initiative" to highlight COVID-19 data-collecting and reporting inconsistencies that led to confusion for policymakers and the public. Why it matters: Lack of granular data on cases, deaths — and now vaccination rates — has been a nationwide hindrance in targeting communities who needed more outreach or resources this past year, Axios' Marisa Fernandez writes. Context: Johns Hopkins became a key resource for data during the COVID-19 pandemic as one of the few institutions that tracked global cases, deaths and recoveries. "The opportunity to do it better is abundant," Beth Blauer, associate vice provost for public sector innovation at JHU, tells Axios. The state of play: At the beginning of the pandemic, states and local governments were left to their own devices to determine how they would report COVID-19 data. How it works: The Pandemic Data Initiative will feature ongoing analysis spotlighting data challenges and irregularities. The initiative will be a part of its Coronavirus Resource Center, where the team will also link up with leaders in the public health field to highlight solutions for the COVID pandemic and future crises. Go deeper: COVID-19 lessons for trapping the next pandemic     A message from Blue Cross Blue Shield Association Reducing racial disparities in maternal health     Women of color are two to three times more likely to die from pregnancy-related complications than white women. See how Blue Cross and Blue Shield companies nationwide are working to reduce racial disparities in maternal health by 50% in five years.     4. Sanofi, GSK vaccine shows strong immune response Sanofi and GSK announced this morning their COVID-19 vaccine candidate demonstrated a strong immune response in adults in a phase 2 clinical trial. Why it matters: Sanofi and GSK say their recombinant protein-based vaccine candidate could ultimately serve as a universal COVID-19 vaccine booster, able to boost immunity regardless of the vaccination first received. It could also ultimately help ease the ongoing global supply needs for vaccines. Details: Sanofi and GSK said the vaccine triggered an antibody response in 95% to 100% of all the trial participants, ages 18 to 95, who got the vaccine. The companies also observed a "high immune response after a single dose in patients" who previously recovered from COVID-19, which shows the vaccine has strong booster potential. It's a promising development after the companies had to delay their vaccine in December to improve immune response in older adults. Still, it's also important to point out this is a phase 2 clinical trial, a relatively small study with 722 volunteers in the U.S. and Honduras. A global Phase 3 trial with more than 35,000 participants from various countries is expected to start in the coming weeks to test the efficacy of two vaccine formulations against variants, officials said. In parallel, the companies also plan to conduct booster studies. Should the candidate prove successful in clearing Phase 3 testing and other regulatory hurdles, officials said a vaccine could be approved by the end of 2021.     5. Catch up quick Illustration: Aïda Amer/Axios   Critical emergency medical records systems remain offline at San Diego-based Scripps Health two weeks after the health system was hit by a ransomware attack, the San Diego Union-Tribune reports. The Biden administration revoked a Trump-era regulation that would have required green-card applicants abroad to show they have health care coverage — or the means to pay for it — before being allowed to come to the U.S., the Wall Street Journal reports. With surges in mental health cases from children in emergency rooms across Minnesota, hospitals are reaching a capacity crisis that's forcing young people to wait days and weeks for critical care, the Minneapolis Star Tribune reports.     A message from Blue Cross Blue Shield Association Making health coverage more affordable     Enhanced premium assistance that makes health care coverage more affordable will end in 2022. See how Congress can help millions of middle class families by expanding coverage, reducing costs and making health care more equitable for everyone.     Axios thanks our partners for supporting our newsletters. Sponsorship has no influence on editorial content. Axios, 3100 Clarendon B‌lvd, Suite 1300, Arlington VA 22201   You received this email because you signed up for newsletters from Axios. Change your preferences or unsubscribe here.   Was this email forwarded to you? Sign up now to get Axios in your inbox.   Follow Axios on social media: